Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China.

Recombinant adeno-associated virus (rAAV) vectors have emerged as a leading viral vector for in vivo gene therapy because they offer significant advantages over other viral vectors, such as stable physicochemical properties, low pathogenicity, low in…

Preview only. Read the full abstract at the source